Abbott Laboratories ABT
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 48.23B | 46.59B | 45.13B | 44.33B | 43.84B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 48.23B | 46.59B | 45.13B | 44.33B | 43.84B |
| Cost of Revenue | 20.76B | 20.20B | 19.73B | 19.31B | 19.28B |
| Gross Profit | 27.47B | 26.38B | 25.40B | 25.02B | 24.57B |
| SG&A Expenses | 14.48B | 13.28B | 12.36B | 11.69B | 11.49B |
| Depreciation & Amortization | 2.34B | 1.92B | 1.68B | 1.68B | 1.73B |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.88B | 38.55B | 36.75B | 35.61B | 35.42B |
| Operating Income | 7.35B | 8.04B | 8.38B | 8.72B | 8.42B |
| Income Before Tax | 6.56B | 7.51B | 8.14B | 8.47B | 8.14B |
| Income Tax Expenses | 1.86B | 2.09B | 1.86B | 1.94B | -5.84B |
| Earnings from Continuing Operations | 4.70K | 5.43K | 6.28K | 6.52K | 13.98K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.70B | 5.43B | 6.28B | 6.52B | 13.98B |
| EBIT | 7.35B | 8.04B | 8.38B | 8.72B | 8.42B |
| EBITDA | 11.26B | 11.48B | 11.55B | 11.84B | 11.55B |
| EPS Basic | 2.68 | 3.10 | 3.59 | 3.73 | 8.01 |
| Normalized Basic EPS | 2.38 | 2.72 | 2.94 | 3.06 | 2.96 |
| EPS Diluted | 2.67 | 3.08 | 3.56 | 3.71 | 7.97 |
| Normalized Diluted EPS | 2.38 | 2.71 | 2.94 | 3.05 | 2.96 |
| Average Basic Shares Outstanding | 6.96B | 6.97B | 6.98B | 6.97B | 6.97B |
| Average Diluted Shares Outstanding | 6.97B | 6.99B | 6.99B | 6.99B | 6.99B |
| Dividend Per Share | 2.52 | 2.48 | 2.44 | 2.40 | 2.36 |
| Payout Ratio | 91.98% | 78.54% | 66.73% | 63.09% | 28.93% |